Australia's National Health and Medical Research Council (NHMRC) has advised that puberty blockers are appropriate for the gender-affirming care of transgender children in certain circumstances, following a year-long review of international evidence. The interim national clinical practice guidelines, released on Monday, could pressure state and territory governments to reconsider bans on the treatment in public hospitals.
The federal government commissioned the NHMRC—Australia's largest medical research organisation—to develop the advice after Queensland and the Northern Territory imposed bans on puberty suppressants in public hospitals. The New Zealand government later followed suit, despite widespread opposition from the health sector and warnings that such bans would harm children.
What Are Puberty Blockers and Why Are They Controversial?
Puberty blockers are a class of drugs that stop the body from producing oestrogen and testosterone. They are used to delay puberty in transgender young people, giving them more time to explore their gender identity before irreversible physical changes occur.
The use of puberty blockers has been fiercely debated. Supporters argue they are a safe, reversible intervention that can prevent distress and improve mental health outcomes. Opponents raise concerns about long-term effects on bone density and brain development, and some advocate for a 'wait and see' approach before initiating any medical treatment.
What the NHMRC Guidelines Recommend
The NHMRC's interim guidelines advise conditional use of puberty suppressants for children. This means the treatment is considered appropriate in certain circumstances, likely involving careful assessment by multidisciplinary teams and informed consent.
Critically, the council explicitly rejected alternative approaches such as the 'wait and see' model, stating that withholding care 'can affect the young person's physical and mental health, wellbeing, and ability to function'. This is a strong endorsement of gender-affirming care principles.
Implications for State and Territory Bans
Queensland and the Northern Territory currently ban puberty blockers in public hospitals. The NHMRC's advice could put pressure on these governments to lift their bans, as it provides a national clinical benchmark supporting conditional access.
However, the guidelines are interim, and final recommendations may take time. The federal government has not indicated whether it will tie funding to compliance with the guidelines, but the political and ethical pressure is likely to mount.
Reactions from Health Professionals and Advocates
Health professionals have largely welcomed the NHMRC's review, seeing it as a rigorous, evidence-based foundation for clinical practice. Advocates for transgender youth argue that the guidelines affirm the importance of access to care and reject harmful delays.
Opponents of gender-affirming care are likely to criticise the guidelines as premature or insufficiently cautious. The debate is far from over, but the NHMRC's stance provides a significant counterweight to restrictive policies.
What to Watch Next
The final guidelines are expected to be released after further consultation. State and territory governments will face decisions about whether to maintain bans or align with national advice. Meanwhile, families and clinicians will look to the guidelines for clarity on eligibility criteria and safeguards. The background to this story is set out in Australia: latest articles.
- NHMRC advises conditional use of puberty blockers for transgender children.
- Guidelines reject 'wait and see' approach as withholding care.
- Queensland and Northern Territory bans may face pressure to change.
- Final guidelines pending further consultation.
- Health sector broadly supports evidence-based approach.
| State/Territory | Current Policy on Puberty Blockers | Potential Impact of NHMRC Advice |
|---|---|---|
| Queensland | Banned in public hospitals | Pressure to lift ban |
| Northern Territory | Banned in public hospitals | Pressure to lift ban |
| New South Wales | No blanket ban | May adopt guidelines |
| Victoria | Accessible through gender clinics | Likely to align |
FAQ
What did the NHMRC recommend?
The NHMRC recommended conditional use of puberty blockers for transgender children, meaning they are appropriate in certain circumstances. The guidelines reject the 'wait and see' approach as harmful.
Why did the federal government commission this review?
The review was commissioned in response to bans on puberty blockers in Queensland and Northern Territory public hospitals. The government sought national clinical guidance based on international evidence.
Will this change state bans?
The guidelines could pressure state and territory governments to reconsider bans, but they are not legally binding. It remains to be seen how governments will respond.
What are puberty blockers?
Puberty blockers are drugs that suppress the production of oestrogen and testosterone, delaying physical changes of puberty. They are used in gender-affirming care for transgender youth.